0
0
Read Time:46 Second
Partnership Overview
BioNet, a Franco-Thai vaccine biotech company, has partnered with Indonesia’s state-owned PT Bio Farma to co-develop and distribute a TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis) across Southeast Asia.
Technology and Expertise Sharing
- BioNet contributes its proprietary recombinant pertussis technology and extensive global clinical experience.
- Bio Farma provides large-scale manufacturing capabilities and regional public health infrastructure.
Key Objectives
- Accelerate TdaP vaccine availability in ASEAN from 10–15 years to under 5 years.
- Target 10–15 million doses annually, valued at approximately $200 million.
- Enhance pandemic preparedness, vaccine supply chain resilience, and equitable healthcare access in the region.
Operational Roles
- Bio Farma: Leads clinical trials and regulatory filings in Indonesia.
- BioNet: Oversees regulatory and market access for other ASEAN countries.
Strategic Impact
- Supports ASEAN’s immunisation programs with a regionally developed and produced vaccine.
- Aligns with broader goals of regional health security and self-sufficiency in vaccine production.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
